Structure-based engineering of minimal proline dehydrogenase domains for inhibitor discovery

被引:2
|
作者
Bogner, Alexandra N. [1 ]
Ji, Juan [1 ]
Tanner, John J. [1 ,2 ]
机构
[1] Univ Missouri, Dept Biochem, Columbia, MO 65211 USA
[2] Univ Missouri, Dept Chem, Columbia, MO 65211 USA
来源
基金
美国国家卫生研究院;
关键词
enzyme inhibition; enzyme kinetics; protein engineering; X-ray crystallography; THERMUS-THERMOPHILUS; ESCHERICHIA-COLI; ACTIVE-SITE; PROTEIN; BINDING; METABOLISM; OXIDASE; EXPRESSION; SAXS; CRYSTALLIZABILITY;
D O I
10.1093/protein/gzac016
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proline dehydrogenase (PRODH) catalyzes the FAD-dependent oxidation of l-proline to Delta(1)-pyrroline-5-carboxylate and is a target for inhibitor discovery because of its importance in cancer cell metabolism. Because human PRODH is challenging to purify, the PRODH domains of the bacterial bifunctional enzyme proline utilization A (PutA) have been used for inhibitor development. These systems have limitations due to large polypeptide chain length, conformational flexibility and the presence of domains unrelated to PRODH activity. Herein, we report the engineering of minimal PRODH domains for inhibitor discovery. The best designs contain one-third of the 1233-residue PutA from Sinorhizobium meliloti and include a linker that replaces the PutA alpha-domain. The minimal PRODHs exhibit near wild-type enzymatic activity and are susceptible to known inhibitors and inactivators. Crystal structures of minimal PRODHs inhibited by S-(-)-tetrahydro-2-furoic acid and 2-(furan-2-yl)acetic acid were determined at 1.23 and 1.72 angstrom resolution. Minimal PRODHs should be useful in chemical probe discovery.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology
    Lu, Min
    Zhang, Hongjun
    Li, Derun
    Childers, Matthew
    Pu, Qinglin
    Palte, Rachel L.
    Gathiaka, Symon
    Lyons, Thomas W.
    Palani, Anandan
    Fan, Peter W.
    Spacciapoli, Peter
    Miller, J. Richard
    Cho, Hyelim
    Cheng, Mangeng
    Chakravarthy, Kalyan
    O'Neil, Jennifer
    Eangoor, Padmanabhan
    Beard, Adam
    Kim, Hai-Young
    Sauri, Josep
    Gunaydin, Hakan
    Sloman, David L.
    Siliphaivanh, Phieng
    Cumming, Jared
    Fischer, Christian
    ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (09): : 1380 - 1388
  • [42] Fragment approaches in structure-based drug discovery
    Hubbard, Roderick E.
    JOURNAL OF SYNCHROTRON RADIATION, 2008, 15 (227-230) : 227 - 230
  • [43] Structure-based discovery of nonhallucinogenic psychedelic analogs
    Cao, Dongmei
    Yu, Jing
    Wang, Huan
    Luo, Zhipu
    Liu, Xinyu
    He, Licong
    Qi, Jianzhong
    Fan, Luyu
    Tang, Lingjie
    Chen, Zhangcheng
    Li, Jinsong
    Cheng, Jianjun
    Wang, Sheng
    SCIENCE, 2022, 375 (6579) : 403 - +
  • [44] Structure-based drug discovery for Plasmodium falciparum
    Mehlin, C
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2005, 8 (01) : 5 - 14
  • [45] Structure-based ligand discovery for nutrient transporters
    Schlessinger, Avner
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [46] New Targets for Structure-Based Drug Discovery
    Andrews, Steve
    Congreve, Miles
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2017, 17 (01) : 2 - 3
  • [47] Structure-Based Drug Discovery with Deep Learning
    Ozcelik, R.
    van Tilborg, D.
    Jimenez-Luna, J.
    Grisoni, F.
    CHEMBIOCHEM, 2023,
  • [48] Structure-Based Drug Discovery for Botulinum Neurotoxins
    Swaminathan, Subramanyam
    BOTULINUM NEUROTOXINS, 2013, 364 : 197 - 218
  • [49] Needle in the haystack: structure-based toxin discovery
    Fieldhouse, Robert J.
    Merrill, A. Rod
    TRENDS IN BIOCHEMICAL SCIENCES, 2008, 33 (11) : 546 - 556
  • [50] Structure-based screening and design in drug discovery
    van Dongen, M
    Weigelt, J
    Uppenberg, J
    Schultz, J
    Wikström, M
    DRUG DISCOVERY TODAY, 2002, 7 (08) : 471 - 478